Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Results Of A Phase Ii Trial Of Ramucirumab Plus Irinotecan As Second-Line Treatment For Patients With Advanced Gastric Cancer (Hgcsg 1603)

Yasuyuki Kawamoto,Satoshi Yuki,Kentaro Sawada,Michio Nakamura,Osamu Muto,Susumu Sogabe,Yoshiaki Shindo,Atsushi Ishiguro,Atsushi Sato,Yasushi Tsuji,Masayoshi Dazai,Hiroyuki Okuda,Takahide Sasaki,Kazuaki Harada,Shintaro Nakano,Hiroshi Nakatsumi,Mari Sekiguchi,Yuh Sakata,Naoya Sakamoto,Yoshito Komatsu

JOURNAL OF CLINICAL ONCOLOGY（2021）

Cited 6|Views10
No score
Abstract
217Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased over...
More
Translated text
Key words
advanced gastric cancer,gastric cancer,ramucirumab,irinotecan,second-line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined